BioCryst Pharmaceuticals is trading 4.26% down at $9.41 after no clear negative company-specific catalyst was identified for August 26, 2026.
- The latest company announcement was Japan’s August 25 approval of ORLADEYO for pediatric hereditary angioedema patients, generally positive rather than an evident explanation for the decline.
- Broader futures were only modestly lower, so market sentiment does not clearly explain the move.